Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $25.3652W HIGH $61.70
Volume
595.66 K
Value Traded
22.07 M
Short % Float
8.76%
-4.17%Week
-0.36%1 Month
+54.14%3 Month
+87.18%6 Month
-60.8%5 Year
+133.8%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
2.69 B
EPS (TTM)
0.21
P/E Ratio
254.77
Ent. Value
2.58 B
Total Shares
50.85 M
Float Shares
48.87 M
Insiders
3.92%
Institutions
104.93%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
ATRC Catalyst Timeline
Dated clinical, regulatory and corporate events for AtriCure, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for AtriCure, Inc.
5Total events
1Upcoming
0Tier-1 (high impact)
2026 to 2026Coverage
Upcoming catalysts 1
TBD
T2Timing Guidance
Subscribe to view catalyst details
Event history 3
Past FDA Catalysts and PDUFA Decisions
How ATRC actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D26 / 100
Pipeline Score
$0M
Pipeline Value
Not rated
Valuation Signal
4
Drugs Scored
-
rNPV / MCap
Top 79%
Small Cap(rank 520 of 658)
Percentile Rank
AtriCure, Inc. faces pipeline headwinds (26/100), with 4 assets in development.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|
Clinical Trial Results
Readouts, endpoints and source filings for every ATRC program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| hybrid Convergent procedure | atrial fibrillation | 2020-05-08 | effectiveness difference: 18%; MAE rate: 7.8%; performance goal: 12%; Afib burden reduction: >90%; advantage over control: >23%Read More | May 8 , 20 20  AtriCure Announces Results from CONVERGE IDE Clinical Trial  R esults presented virtually via Heart Rhythm 365 Platform ; show s primary effectiveness superiority in fRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Privitera SalvatoreOfficer (Chief Technical Officer) | Sell | -4,519 142,745 held | $60.00 | 09/23/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ATRC
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| DAFNA Capital Management LLC | 3.2 % (-17.9 %) | 16.72 M | 597.43 K |
ATRC Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ATRC ranks across every disease it competes in
Competitive Position is a premium feature
See how ATRC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialATRC News
ATRCAtriCure to Participate in the 2026 Wells Fargo Health Care Conference
AtriCure, Inc. (Nasdaq: ATRC) announced its participation in the 2026 Wells Fargo Health Care Conference. The company's management will engage in a fireside chat scheduled for September 8, 2026, at 10:15 a.m. Eastern Standard Time. This event underscores AtriCure's commitment to transparency and stakeholder engagement.
Read more →ATRC▲ +6.6%on this news
AtriCure to Participate at Upcoming Investor Conferences
AtriCure, Inc. has announced its participation in two upcoming investor conferences, highlighting its role as a leader in surgical treatments for atrial fibrillation and related therapies. The management team will present at the 11th Annual Needham Virtual MedTech & Diagnostics Conference scheduled for August 10, 2026. This engagement reflects the company's commitment to investor relations.
Read more →ATRC▲ +6.2%on this news· ran to +24% by day 3shared move
AtriCure Reports Second Quarter 2026 Financial Results
AtriCure, Inc. has reported its financial results for the second quarter of 2026, highlighting healthy growth and a notable increase in profitability. CEO Michael Carrel emphasized the effectiveness of their innovative technologies in surgical treatments for atrial fibrillation and related areas. The company continues to strengthen its position in the market.
Read more →ATRC▲ +6.9%on this news
AtriCure to Announce Second Quarter 2026 Financial Results
AtriCure is set to announce its financial results for the second quarter of 2026. The announcement is expected to provide insights into the company's performance during this period. Further details regarding the specific date and time of the announcement have not been disclosed.
Read more →ATRCAtriCure to Participate in the Goldman Sachs 47th Annual Global Health Care Conference
AtriCure is set to participate in the Goldman Sachs 47th Annual Global Health Care Conference. The event is a significant platform for discussing advancements in health care. Further details on AtriCure's agenda or focus during the conference have not been provided.
Read more →ATRCAtriCure Reports First Quarter 2026 Financial Results
AtriCure, Inc. reported its financial results for the first quarter of 2026, revealing a worldwide revenue of $141.2 million, which marks a 14.3% increase compared to the same period last year. The company achieved net income of $0.1 million and an adjusted EBITDA of $17.1 million, showcasing improved profitability. U.S. revenue accelerated by 14.9%, supported by strong sales of key products including AtriClip and cryoSPHERE MAX. AtriCure expects continued growth with projected 2026 revenue between $600 million to $610 million.
Read more →ATRCAtriCure to Participate in the 2026 Bank of America Securities Health Care Conference
AtriCure, Inc. will participate in the 2026 Bank of America Securities Health Care Conference. The management is set to engage in a fireside chat on May 12, 2026. This event will be accessible via a live audio webcast on the company's investor relations website. AtriCure is noted for its innovative technologies in treating atrial fibrillation and related conditions.
Read more →ATRCAtriCure to Announce First Quarter 2026 Financial Results
AtriCure is set to announce its financial results for the first quarter of 2026. This announcement is anticipated by stakeholders and may provide insights into the company's performance. The specific details of the results have not been disclosed yet.
Read more →ATRCAtriCure to Participate in the Citizens Life Sciences Conference
AtriCure, Inc. will participate in the Citizens Life Sciences Conference on March 10, 2026. The company's management will engage in a fireside chat, accessible via a live audio webcast. AtriCure is recognized for its innovative technologies in treating atrial fibrillation and related conditions, with a significant global impact.
Read more →ATRCAtriCure Reports Fourth Quarter 2025 and Full Year 2025 Financial Results
AtriCure, Inc. announced its financial results for Q4 2025 and the full year of 2025, highlighting a 13.1% increase in quarterly revenue to $140.5 million. The company achieved a net income of $1.8 million in Q4, alongside a positive adjusted EBITDA of $19.9 million. Although the full year saw a net loss of $11.4 million, there was notable revenue growth of 14.9% year-over-year, driven by new product adoption. Looking forward, AtriCure projects 2026 revenue to reach approximately $600-$610 million, indicating continued growth ambitions.
Read more →ATRCAtriCure to Announce Fourth Quarter and Full Year 2025 Financial Results
AtriCure, Inc. will announce its fourth quarter and full year 2025 financial results on February 17, 2026. An audio webcast will be held at 4:30 p.m. ET to discuss these results. AtriCure is known for its innovative technologies in treating atrial fibrillation and related conditions, with a significant global impact.
Read more →ATRC▼ -9.2%on this news
Preliminary Results for Fourth Quarter and Full Year 2025, Provides Financial Outlook for 2026
AtriCure, Inc. has announced preliminary financial results for the fourth quarter and full year of 2025, indicating a strong expected growth trajectory. For 2026, the company projects revenues between $600 million and $610 million, supported by positive cash flow and an increase in product adoption. The company has also reported a positive adjusted EBITDA outlook for the upcoming year, reflecting robust financial performance. These figures follow a successful year marked by innovation in surgical treatments for atrial fibrillation and related conditions.
Read more →ATRCAtriCure to Participate in the J.P. Morgan 44th Annual Healthcare Conference
AtriCure, Inc. will participate in the J.P. Morgan 44th Annual Healthcare Conference on January 14, 2026. The company's management will present at 10:30 a.m. PST, and interested parties can access the live audio webcast via their website. AtriCure is known for its innovative technologies in treating atrial fibrillation and related conditions.
Read more →ATRCAtriCure Announces the First Patients Treated with Novel Dual Energy Platform
AtriCure, Inc. has announced the successful first-in-human treatments using its new dual energy platform that integrates Pulsed Field Ablation (PFA) with Advanced Radiofrequency Ablation (Advanced RFA). The procedures, performed in Australia, demonstrated significant reductions in ablation time, enhancing surgical efficiency. However, the technologies are not yet approved for market use, and clinical trials are expected to commence next year.
Read more →ATRCAtriCure Reports Third Quarter 2025 Financial Results Raises Financial Outlook for 2025
AtriCure, Inc. reported third quarter financial results for 2025, showing significant year-over-year revenue growth of 15.8% to $134.3 million. The net loss decreased to $0.3 million, marking an improvement of $7.6 million from the previous year. Adjusted EBITDA rose by $9.9 million to $17.8 million, demonstrating strong operational performance. The company raised its full year revenue guidance to approximately $532 million to $534 million and continues to focus on expanding its suite of surgical products for atrial fibrillation management.
Read more →ATRCAtriCure Reports Second Quarter 2025 Financial Results Raises Financial Outlook for 2025
AtriCure, Inc. reported a robust second quarter for 2025 with revenues reaching $136.1 million, up 17.1% year over year. Despite a net loss of $6.2 million, the company showed improved adjusted EBITDA of $15.4 million. The completion of 6,500 patient enrollments in the LeAAPS trial marks a significant advancement for AtriCure. The company raised its financial outlook for 2025, expecting revenues between $527 million and $533 million, demonstrating confidence in its growth trajectory.
Read more →ATRCAtriCure Reports First Quarter 2025 Financial Results
AtriCure reported its first quarter 2025 financial results, showing a revenue increase to $123.6 million, up 13.6% year over year. The company also improved its net loss to $6.7 million, an enhancement of $6.5 million compared to the previous year. Adjusted EBITDA rose to $8.8 million, marking a significant $6.0 million increase year over year. Management forecasts a projected revenue range of $517 million to $527 million for the full year 2025, highlighting optimism in continued growth.
Read more →ATRCAtriCure, Inc. All rights reserved. 2 Forward Looking Statements and Non-GAAP Financial Measures This presentation and oral statements made in connection with this presentation contain "forward-looking statements," which
AtriCure, Inc. has outlined its commitment to innovation and clinical science as it navigates through forward-looking statements regarding future growth opportunities. The company is strategically expanding its market presence in various cardiac and pain management sectors while emphasizing the importance of robust education and awareness initiatives. Recent changes in CMS guidelines and the introduction of new surgical codes may further support its operational efforts, enhancing patient access to cutting-edge treatments. Overall, AtriCure appears poised for sustained growth in upcoming years amidst evolving healthcare landscapes.
Read more →About AtriCure, Inc.
Headquarters7555 INNOVATION WAY, MASON, OH, 45040
Founded1994
BIOPHARMAWATCH ELITE PLUS
Trade the next ATRC catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime